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Abstract
Integrating a desired DNA sequence into the yeast genomes is a widely-used
genetic manipulation in the budding yeast  . TheSaccharomyces cerevisiae
conventional integration method is to use an integrative plasmid such as pRS
or YIplac series as the target DNA carrier. The nature of this method risks
multiple integrations of the target DNA and the potential loss of integrated DNA
during cell proliferation. In this study, we developed a novel yeast integration
strategy based on the widely used CRISPR-Cas9 system and created a set of
plasmids for this purpose. In this system, a plasmid bearing Cas9 and gRNA
expression cassettes will induce a double-strand break (DSB) inside a
biosynthesis gene such as Met15 or Lys2. Repair of the DSB will be mediated
by another plasmid bearing upstream and downstream sequences of the DSB
and an integration sequence in between. As a result of this repair the sequence
is integrated into genome by replacing the biosynthesis gene, the disruption of
which leads to a new auxotrophic genotype. The newly-generated auxotroph
can serve as a traceable marker for the integration. In this study, we
demonstrated that a DNA fragment up to 6.3 kb can be efficiently integrated
into the Met15 or Lys2 locus using this system. This novel integration strategy
can be applied to various yeasts, including natural yeast isolated from wild
environments or different yeast species such as  .Candida albicans
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      Amendments from Version 1
Changes made according to Reviewer 2-Stefan H.  Millson:
1.    Third paragraph of the introduction changed “this system” to 
“these systems”.
2.    Same paragraph changed “overcome” to “circumnavigated”.
3.    Changed centrifuge speed in methods from rpm to x g.
4.    Changed the description of amount of Taq amount from 
volume to units in Methods.
Changes made according to Reviewer 3-Barry Panaretou:
1.    In Figure 3 and Figure 4, the expected sizes of PCR fragments 
are indicated in the figure legends.
2.    The molecular weight markers migrating above and below the 
relevant PCR products were also indicated in the figures.
3.    A reference suggested by this reviewer (The CRISPR/Cas9 
system of Mans et al. 2015) was added. The main difference 
between that system and the one described in this manuscript 
is that the integration mediated by this system produces 
a new auxotrophic marker, which facilitate further genetic 
manipulation. This has been emphasized in the introduction 
and discussion sections.
4.    In line 1, 'DNA sequence into yeast genome' was changed to 
'DNA sequence into the yeast genome'.
5.    In Line12, '...the sequence is integrated into genome' is 
changed to '...the sequence is integrated into the genome' 
6.    In line 1 of the second paragraph of the Introduction, 
‘available for the yeast genome' was changed to ‘available for 
the yeast genome.
7.    In the paper, 'homologue repair' was replaced with 
'homologous repair' and 'homologue sequences' was 
replaced with 'homologous sequences'. 
8.    On diagram at top of page 5, 'homolog' was replaced by 
'homologue'.
9.    One of repetitive ‘described' was removed at end of 
paragraph on page 4.
10. At end of page 6, column heading was changed to 'Number 
of transformants'.
See referee reports
REVISED
a yeast biosynthesis gene. The most commonly used nutritional 
markers are the URA3, LEU2, TRP1, and HIS3 genes, which are 
required for synthesis of pyrimidine, L-leucine, L-tryptophan, 
and L-histidine respectively. To integrate these vectors into yeast 
genome, these circular plasmids are first linearized by restriction 
digestion occurring inside the nutritional marker genes. 
After transformation, the linearized vectors can be integrated 
into the nutritional marker gene locus in the yeast genome 
through HR. It is important that the host yeast cells should 
harbor the corresponding auxotrophic mutation or deletion 
(also called auxotrophic marker) for the selection of the 
successful transformants. The consequence of this integration 
is the target DNA sequence being flanked by a mutated allele 
and a wild-type allele of the nutritional marker. Therefore, the 
yeast cells acquiring the integrative vector become prototrophic 
for the corresponding nutritional marker4.
Several drawbacks of these systems have been known to limit 
its application. First, the corresponding auxotrophic marker is 
required for the selection of transformants. For example, the 
LEU2 integrative plasmid only can be used in cells with a leu2 
auxotrophic marker, which is unavailable in some yeast labora-
tory strains. More seriously, a yeast strain isolated from a wild 
environment would lack all of the available auxotrophic markers, 
which makes the application of this system impossible in these 
cells. Thirdly, the short supply of existing nutritional markers 
limits the application of this commonly used system in some 
laboratory strains. Moreover, the integrated DNA sequence 
flanked by the wild-type and mutant genes can be looped out 
from yeast genome by random recombination between these two 
homologous sequences4. This event can result in leaving behind 
either the wild-type or mutant gene on the chromosome depend-
ing on the site where the recombination occurs. In this case, 
a prototroph genotype of offspring arising from the original 
transformant would not guarantee the maintenance of the 
integrated DNA sequence in the genome. Finally, the manner 
of this integration can lead to tandem repeats of the sequence, 
which can cause undesirable overexpression of the target gene. 
To circumnavigate these problems, new strategies have been 
developed. For example, a DNA fragment containing the inte-
gration DNA sequence plus an antibiotic marker can be inserted 
into the yeast genome by replacing the leu2 or homothallic 
switching endonuclease (HO) sequence5,6. Although this method 
avoids multi-integration and instability of integration, it requires 
an extra antibiotic marker. Furthermore, including the extra 
sequence for the antibiotic marker will restrict the size of the 
integration sequence since the integration efficiency of a longer 
DNA sequence is reduced.
The CRISPR-Cas9 system has been extensively used to modify 
the genome in eukaryotes including yeast7,8. It is composed 
of a Cas9 nuclease that generates a DNA double strand break 
(DSB), and a guide RNA (gRNA) that precisely recruits the 
Cas9 nuclease to a target DNA sequence. By harnessing this 
system, a strategy for a marker-free integration involving a 
template DNA sequence can be used for the repair of the DSB. 
As a result of this repair, the desired DNA sequence is 
integrated into the DSB site9. This method avoids all of the 
mentioned limitations for conventional integration approaches. 
Introduction
The budding yeast Saccharomyces cerevisiae has been widely 
used as a model organism for basic research in all aspects of 
eukaryotic biology. With at least 31% of S. cerevisiae’s more 
than 6000 genes having homologues in the human genome1, 
the insight gained from yeast-focused investigation greatly 
benefits our understanding of the molecular basis of human 
pathogenesis, such as cancer and Alzheimer’s disease.
There are many versatile and powerful tools available for the 
yeast genome manipulation, which contribute to the popularity 
of yeast as a model organism. For example, a DNA fragment 
can be integrated by homologous recombination (HR) into the 
yeast genome, allowing the expression of an exogenous gene or 
modified yeast gene. A traditional integration method of choice, 
namely the YIplac-series2 or pRS-series3 integrative vectors, has 
been successfully used to this end for several decades. An 
integrative plasmid typically uses an E. coli cloning vector as 
the backbone and contains a yeast nutritional marker, normally 
Page 3 of 14
Wellcome Open Research 2018, 3:72 Last updated: 27 JUL 2018
However, the integration is difficult to trace in later genetic 
manipulations due to the lack of a genetic marker. We present 
here a set of CRISPR-Cas9 plasmids and corresponding repair 
plasmids that make integration more practical, flexible and 
traceable. The CRISPR-Cas9 plasmid is used to introduce a 
single DSB in a gene encoding an essential biosynthesis enzyme. 
The repair plasmid provides a linear target DNA sequence 
flanked by sequences homologous to each side of the DSB, 
which is used as a template sequence for homologous repair 
(HR) of the DSB. As a consequence, the biosynthesis gene is 
replaced with the integrating DNA sequence. This leads to a new 
auxotrophic genotype, which can be used as a genetic marker 
for the integration. In this study, we constructed two sets of 
CRISPR-based yeast integration systems targeting Lys2, an 
A-aminoadipate reductase for biosynthesis of lysine, and Met15, 
an O-acetyl homoserine-O-acetyl serine sulfhydrylase for 
biosynthesis of methionine. We also demonstrated the efficient 
integration achieved by these systems.
Methods
Yeast and Escherichia coli culture
All yeast strains used in this study were derived from W303 
(Mat a, ade2-1, trp1-1, can1-100, leu2-3,112, his3-11,15, 
ura3-52). Yeast cells were grown in rich medium (yeast extract 
peptone; YEP) supplemented with 2% glucose (yeast extract 
peptone dextrose; YPD) or synthetic complete (SC) medium 
at 30°C. Cultures were agitated at 200rpm (Kühner Shaker). 
YPD-Nat plates contained YEP medium with 2% glucose and 
100 µg/ml clonNAT (Catalog No N5375-74, Stratech Scientific, 
UK). E. coli strain XL1-Blue (Catalog No 200249, Agilent Tech-
nologies) was used for plasmid manipulation. The E. coli standard 
media and transformation were described as previously10.
Plasmid construction
The plasmids expressing gRNAs targeting Lys2 and Met15 
were derived from the plasmid pBH257 (a gift from Prof. 
Kim Nasmyth’s lab). The pBH257 is a pRS425-based plasmid 
bearing a Cas9 endonuclease expression cassette and a SNR52 
promoter-controlled gRNA-encoding sequence. This plasmid 
also contains two SapI restriction endonuclease sites down-
stream of the SNR52 promoter for insertion of a 20bp targeting 
DNA sequence. To construct the CRISPR plasmids targeting 
Lys2 or Met15, a pair of oligonucleotides (5µM each in 50mM 
NaCl solution) with complementary targeting sequences were 
annealed by incubation in a PCR machine (ProFlex™ PCR 
System, Life technology) at the following temperatures: 95°C 
for 2min, 72°C for 2min, 50°C for 2min, and 25°C for 2min. 
The annealed DNA was ligated with the SapI-digested 
pBH257 plasmid (Catalog No 6022, Takara DNA Ligation Kit, 
Version 2.1, Clontech) and transformed into E. Coli as described 
previously10.
To construct the repair plasmids for the repair of the DSB 
occurring inside Lys2 or Met15, two 1 kb DNA fragments 
containing the upstream and downstream sequences of Lys2 
or Met15 were amplified by PCR and cloned into pBlueScript 
SK- plasmid. To facilitate the cloning of a DNA sequence into the 
repair plasmid, a multi-cloning site was introduced between these 
two homologous sequences. A pair of NotI and PaeI restriction 
endonuclease sites were also inserted at the 5’ end of the upstream 
homologous sequence and at the 3’ end of the downstream 
homologous sequence, which can be used to release the repair 
fragment from the plasmids.
Yeast transformation
Yeast transformation was performed as previously described11. 
Briefly, yeast cells, exponentially grown, were pelleted and 
suspended to a final cell density of 4 × 109 cells/ml with 
100mM lithium acetate. Aliquots (50µl) were pre-incubated at 
30°C for 30 minutes and mixed with 240µl of 50% (w/v) Poly-
ethylene Glycol (PEG), 36µl of 1.0M lithium acetate, 25µl of 
single stranded DNA, and 50µl DNA mixture. The DNA mixture 
contains 2.5µg of Cas9-targeting plasmid and 5µg of NotI 
or PaeI-digested repair plasmid. The cell mixture was incu-
bated for 30 min at 30°C and heat shocked at 42°C for 20 min. 
Cells were then harvested by centrifugation in a microfuge 
(3,000×g; 3 min) and gently resuspended in 7ml of YPD. 
After incubation for 90 minutes at 30°C while gently shak-
ing (100rpm), the cells were spread onto appropriate agar plates 
and incubated at 30°C for 2–3 days.
Quick DNA extraction and diagnostic PCR
The genome DNA used for diagnostic PCR was extracted by 
a LiOAc/SDS method12. The yeast cells grown overnight on 
YPD plates were collected using 1µl inoculation loops and 
suspended in 100µl of lysis solution (200 mM LiOAc and 1% 
SDS). The cells were lysed at 70°C for 10 min. The DNA was 
precipitated by the addition of 300µl of 100% ethanol and 
collected by centrifugation (14,500 g× 5 minutes). Supernatant 
was removed and the pellet was washed with 500 µl of 70% 
ethanol. The DNA was air-dried in an extraction hood for 
15 minutes and dissolved in 100µl of MiniQ water. The debris 
was removed in a micro-centrifuge (14,500 g× 5 minutes) and 
1µl of supernatant was used for a PCR reaction with a final 
volume of 20 µl. The PCR reaction was performed under 
recommended conditions (Catalog No PB10.11, PCRBIO 
HiFi Polymerase, PCR Biosystem). The 20 µl reaction mixture 
consists of l × PCR buffer containing 3mM of MgCl2 and 
1 mM of dNTP, 400 nM of each primer and 1 unit of Taq DNA 
polymerase. Thermo cycle condition was: Initial denatura-
tion at 95°C for 2 min followed by 30 cycles of denaturation at 
95°C for 15 seconds, annealing at 55°C for 15 seconds and 
extension at 72°C for 30 seconds. The sequences for the primers 
used in this study were listed in Table 1. Primers were sourced 
from Integrated DNA Technologies.
Results and discussion
The strategy for the Cas9-mediated integration
In this study, we developed a novel integration system in 
Saccharomyces cerevisiae, which is based on the CRISPR-
Cas9 system. The principle of this system is that the desired 
DNA sequence is integrated into the yeast genome as a conse-
quence of homologous repair of a DSB generated at a specific 
site by the CRISPR-Cas9 system. To facilitate marking of the 
integration, the DSB site is designed to occur at a gene encod-
ing a key enzyme in a biosynthesis pathway (Figure 1). In this 
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Table 1. Primers used in this study.
Primer used in 
this study Sequence
Lys2Cas9F ATCCTTGAGTAGGGACATACAAT
Lys2Cas9R AACATTGTATGTCCCTACTCAAG
Met15cas9F ATCGATACTGTTCAACTACACGC
Met15cas9R AACGCGTGTAGTTGAACAGTATC
Met15OutF ATTTGCGTCATCTTCTAACACCG
Met15OutR TATTATGGCCTCTAGCAGCAACG
Lys2outF AGACCCGCTGGGAGAAGTTCAAG
Lys2outR ATGCTCAACCTTAAGCTGCTGCG
NatF GACCGTCGAGGACATCGAGGTCG
NatR TCGTCGGGGAACACCTTGGTCAG
Figure 1. Flow scheme of the Cas9-mediated integration procedure.
study we chose Lys2 and Met15 as integration sites, which are 
essential enzymes for the synthesis of lysine and methionine. 
To do this, we constructed two pRS425-based episomal 
plasmids, pBH263 and pBH750, each bearing expression cas-
settes for Cas9 and Lys2/Met15-targeting gRNA (Figure 2A). 
When these plasmids were introduced into yeast cells, a DSB 
was produced inside the Lys2 or Met15 gene by Cas9. To 
repair this DSB, a template DNA consisting of the upstream 
and downstream sequences of Lys2/Met15 and the integration 
sequence in between, was co-transformed with the Cas9 plas-
mid. It has been reported that the Cas9-produced DSB can be 
repaired with a template DNA bearing short homologous 
sequences of 50 bp, which can be introduced by PCR with prim-
ers containing these sequences. In this study, we used longer 
homologous sequences (around 400–500 bp) to improve the 
integration efficiency. For this purpose, we constructed two 
repair plasmids, pBH756 and pBH789, which contain two long 
homologous sequences for HR repair and multi cloning sites for 
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Figure 2.  Physical maps of the Cas9/gRNA plasmids (A) and the repair plasmids (B). The positions of the yeast and Escherichia coli 
selection markers and multi cloning sites are indicated.
the insertion of the integration sequence (Figure 2B). To release 
the repair template DNA from these vectors, two NotI/PaeI 
digestion sites were introduced at the both ends of the repair 
cassette. This strategy avoids PCR amplification of the repair 
template DNA, which could introduce mutations and also 
limits the length of the integration fragment. As a result of 
the DSB repair using the repair fragment as the template, the 
target DNA sequence is integrated into the yeast genome by 
replacing MET15 or LYS2 gene. This integration can be PCR- 
verified using two pairs of primers as shown in Figure 1. 
The cells with successful integration become auxotrophic for 
lysine or methionine. This irreversible auxotrophic genotype 
completely genetically links the integrated DNA, so it can be 
used as a reliable marker for the integration.
The integration efficiency of the Cas9-mediated integration
To test the efficiency of Cas9-mediated integration, we used 
NatMX, a dominant nourseothricin-resistance marker, as the 
target DNA sequence. This sequence was cloned into the repair 
plasmids pBH756 and pBH786. The repair template fragment 
bearing the homologous sequences was released by NotI- 
digestion and co-transformed into yeast cells (K699) with the 
Cas9/gRNA LEU2 plasmid (pBH263 or pBH750). The cells 
containing the vectors were selected by growing on SC plates 
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omitting leucine. Using the standard yeast transformation 
protocol described in the methods section, around 400–500 
LEU-positive colonies were obtained in one transformation 
reaction. To achieve a high co-transformation efficacy of the 
template DNA with the Cas9 plasmid, a molecule ratio of 10:1 of 
NatMX DNA to Cas9 plasmid was used in the transformation 
reaction. In this context, we expected that the yeast cells with 
successful integrations would become auxotrophic for methionine 
or lysine (Lys- or Met-) and gain a nourseothricin-resistance 
(NAT+) genotype. To test this, we picked 60 transformants 
randomly from the MET15-targeted or LYS2-targeted inte-
grations and determined their genotypes. This was achieved 
by examining their growth on SC plates omitting methionine/
lysine or YPD plates containing nourseothricin. As shown in 
Table 2 and Table 3, more than 90% of transformants displayed 
NAT+ phenotype, suggesting a high co-transformation efficiency 
of NatMX. Surprisingly, around 20–40% of these transformants 
were still methionine or lysine prototrophic (Met+ or Lys+). 
In these cells, the Cas9 system might have failed to generate 
a DSB. Another explanation is that the DSB repair might have 
produced a mutated allele of Met15 or Lys2 with partial enzyme 
activity still being sufficient for the biosynthesis of methionine 
or lysine. The question was then how the NatMX DNA was 
maintained in the cells since this linear DNA fragment lacks 
a replication origin (ARS). One possibility that this NatMX 
fragment acquired an ARS from genome and self-circularised. 
In this case, the NAT+ genotype will be genetically unsta-
ble. To test this, we crossed ten independent Lys+ NAT+ 
transformants with a wild-type MATA strain (K700). We found 
that all the spores derived from these crosses lost the NAT+ 
Table 2. Genotypes of transformants obtained 
from the co-transformation of Csa9-Met15 and 
NatMX cassette.
Genotype Number of 
transformants
%
Nat resistant,   met- 48 80.0%
Nat resistant,   Met+ 10 16.7%
Nat sensitive,   met- 0 0%
Nat sensitive,   Met+ 1 1.7%
Total 60
Table 3. Genotypes of transformants obtained 
from the co-transformation of Csa9-Lys2 and 
NatMX cassette.
Genotype Number of 
transformants
%
Nat resistant,   lys- 34 56.7%
Nat resistant,   Lys+ 23 38.3%
Nat sensitive,   lys- 0 0%
Nat sensitive,   Lys+ 6 10.0%
Total 60
phenotype (unpublished study, Daniels PW and Hu B). This 
suggested that the NatMX DNA in these cells was not 
integrated into the yeast genome and therefore could be lost 
during mitosis or meiosis.
We also performed tetrad analysis to examine the genetic 
stability of the NAT+ genotype in the Lys- transformants and 
the linkage of NAT+ with lys2. As expected, the segregation of 
the NAT+ genotype for every tetrad derived from 10 crosses 
showed a 2:2 ratio and Lys- co-segregated with the NAT+ 
genotype in all the cases. This indicated that the NatMX cas-
sette was integrated into the Lys2 locus, which led to its disrup-
tion. To further confirm this, we carried out diagnostic PCR 
to examine the right and left junctions resulting from the 
integration using the primer pairs Lys2OutF/NatR and NatF/
Lys2outR (Figure 1). The expected DNA products were 
successfully amplified from all eight Lys- NAT+ transformants, 
revealing correct integrations in these cells (Figure 3A). These 
amplifications failed in the Lys+ NAT+ cells, which was 
consistent with the notion that the NatMX cassette failed 
to be integrated into Lys2 locus (Figure 3A). We also used 
the same strategy to confirm the expected integration of the 
NatMX cassette into the Met15 locus in eight NAT+ Met- 
transformants obtained from the NatMX cassette and pBH750 
co-transformation. These results suggested the transformants 
that gained the auxotrophic genotype were very likely to 
possess the integrated DNA at the expected site. The acquired 
auxotroph can be used a reliable marker to trace the integration 
in later genetic manipulations.
In this study, we have demonstrated the application of our Cas9/
gRNA system for successful integration of a 1.2 kb NatMX 
cassette into the Met15 or Lys2 loci. But, on many occasions, a 
larger fragment is required to be integrated into the yeast genome. 
To explore this possibility, we made an attempt to integrate a 
DNA fragment with a size more than 6kb. We first inserted a 
6.3kb DNA fragment containing the Smc3 encoding sequence 
plus their full promoter and terminator into the repair vectors. 
After co-transformation of the NotI-released repair template 
with the Cas9/gRNA plasmids, around 300–400 transformants 
were obtained on SC –Leu plates. Out of sixteen chosen 
colonies, only around 20% of the transformants acquired the 
expected auxotrophic genotype, suggesting a reduced efficiency 
for the integration of a larger DNA fragment. This could be 
due to the larger DNA being prone to degradation in cells. 
We confirmed that the Lys- or Met- transformants also had 
successful integrations using diagnostic PCR, which produced 
DNA fragments with the expected sizes (Figure 4).
Removal of the Cas9 plasmid
The remaining Cas9/gRNA plasmid in cells with successful 
integrations could affect further genetic operation. For example, 
it could produce undesired DSB during a cross with other cells 
containing wild type LYS2 or MET15. The existence of these 
LEU2 plasmids would prevent the usage of leu2- auxotrophic 
markers in future genetic manipulation. Here, we developed 
a simple method to remove the Cas9/gRNA plasmid from 
the successful transformants. The cells with the integra-
tion of the target DNA were grown in YPD liquid media 
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Figure 4. Diagnostic PCR products that confirm the integration of a 6.3kb Smc3 cassette. (A) Yeast cells (K699) were co-transformed 
with the Cas9-Lys2 plasmid (pBH263) and the Not1-disgested Smc3 cassette (pBH767) and diagnostic PCR were carried out with Lys- LEU+ 
transformants. The primer pairs Lys2outF/Smc3R and Sm3F/Lys2outR were used for checking left and right junction. The expected sizes 
of diagnostic PCR are 1.7 kb for left junction and 1.4 kb for right junction. (B) Yeast cells (K699) were co-transformed with the Cas9-Met15 
plasmid (pBH750) and Not1-disgested Smc3 cassette (pBH766) and diagnostic PCR were carried out in Lys- LEU+ transformants. The 
primer pairs Met15outF/Smc3R and Sm3F/Met15outR were used for checking left and right junction. The expected sizes of diagnostic PCR 
are 1.5 kb for left junction and 1.1 kb for right junction.
Figure 3. Diagnostic PCR confirm the integration of a NatMX cassette. (A) Yeast cells (K699) were co-transformed with the Cas9-Lys2 
plamid (pBH263) and the Not1-disgested NAT cassette (pBH762), designed to be integrated into the Lys2 locus. The transformants were 
selected by plating on SD-LEU plates. Genomic DNA was isolated from the parental yeast K699 (P) and the transformants with the indicted 
genotypes. The PCR reactions were carried out using the primer pairs Lys2outF/NatR for checking left junction (top panel) and NatF/Lys2outR 
for checking right junction (low panel). The expected sizes of diagnostic PCR are 1.3 kb for left junction and 1.4 kb for right junction. (B) Eight 
NAT+ Met- transformants derived from the co-transformation of the Cas9-Met15 plasmid (pBH750) and the Not1-disgested NAT cassette 
(pBH763) were selected for diagnosis PCR. The primer pairs Met15outF/NatR for checking left junction (left panel) and NatF/Met15outR for 
checking right junction (panel panel) were used in the PCR reaction. The expected sizes of diagnostic PCR are 1.2 kb for left junction and 1.1 
kb for right junction. *indicated non-specific amplification.
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overnight. The diluted culture was then spread onto a YPD 
plate to allow the formation of 300–500 colonies. These 
cells were then replica plated onto SC –Leu solid media to 
determine the colonies losing the Cas9/gRNA plasmid. Our 
data showed that more than 80% cells lost this vector after 
an overnight culturing (unpublished study, Daniels PW and 
Hu B).
Conclusion
In this study we developed a Cas9-based genome integra-
tion system in Saccharomyces cerevisiae that overcomes the 
drawbacks of conventional integration methods. To simplify the 
procedure and enhance the flexibility of integration to a great 
extent, we created a set of plasmids including the Cas9/gRNA 
and the corresponding repair vectors. We have demonstrated 
the successful integration of target DNA fragments of a size up 
to 6.3kb. Though only two sites, Lys2 and Met15, were tested 
in this study, many other sites harboring key biosynthesis 
enzymes encoding sequences could be used in this 
system. This would greatly expand available integration sites. 
Furthermore, since the Cas9 system has been proved to work 
efficiently in many eukaryotic organisms, we are optimistic that 
such a strategy could be used in other popularly-studied yeasts, 
especially those lacking sufficient genetic markers, such as 
Candida albicans.
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